This advanced facility is designed to accelerate the development and commercialization of cell therapies, specifically by supporting biotech, biopharma, and translational customers developing cell-based immunotherapies.

Through this new center, cell therapy developers can leverage Thermo Fisher’s expansive product and technology portfolio and deep process optimization knowledge to create comprehensive, end-to-end manufacturing workflows that can scale to enable clinical and commercial success. This initiative is part of Thermo Fisher’s commitment to advancing life sciences and improving patient outcomes through innovative solutions.

"Our new Advanced Therapies Collaboration Center represents a significant milestone in our ongoing commitment to deliver solutions that address critical challenges in cell therapy development. By enabling access to our expertise and broad range of instrumentation, reagents, lab equipment, and analytical solutions, we aim to help our customers overcome manufacturing hurdles and accelerate their path to commercialization," said Betty Woo, Vice President, Cell, Gene and Advanced Therapies, Thermo Fisher Scientific. "By fostering collaboration and innovation, the center is poised to play a pivotal role in helping to advance cell therapies, ultimately improving patient lives."

Cell therapy developers working with Thermo Fisher at the ATxCC will receive support to transition to cGMP manufacturing and address market entry challenges. The center offers access to advanced laboratory equipment and analytical solutions, which can help streamline manufacturing, reduce contamination risks, and promote product consistency. Developers also benefit from expert guidance to optimize manufacturing processes and protocols, ensuring they are scalable and robust. 

The new Carlsbad center builds on Thermo Fisher’s existing collaboration sites in Singapore and Korea, with further expansion planned in Philadelphia to support clinical and commercial cGMP process development.